Clinical Trials on Lower Extremity Deep Venous Thrombosis Recurrent in Australia

Total 26 results

University Medical Center Groningen

Completed

Diagnostic Algorithm in Suspected Upper Extremity Deep Vein Thrombosis (Armour)

Suspected Upper Extremity Deep Vein Thrombosis

Austria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
Medical University of Vienna

Completed

Dialysis Catheter Placement in Patients With Thoracic Central Venous Occlusion

Central Venous Catheter Thrombosis

Austria
Merit Medical Systems, Inc.

Completed

Surfacer System to Facilitate Access in Venous Occlusions (SAVE)

Chronic Venous Thrombosis | Venous Thrombosis Upper Extremity | Venous Thrombosis Upper Extremity Superficial Veins

Austria, Germany, Italy
Medical University of Vienna

Recruiting

Risk of Recurrent Venous Thromboembolism After Provoked Venous Thromboembolism (AURECpro)

Recurrent Venous Thrombosis

Austria
Melbourne Health
Sanofi; National Heart Foundation, Australia

Terminated

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Deep Vein Thrombosis

Australia
Sanofi

Completed

Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs (EQUINOX)

Deep Venous Thrombosis

France, Mexico, Turkey, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, Israel, Netherlands, New Zealand, Poland, Russian Federation, South Africa, Spain
Bristol-Myers Squibb

Completed

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

Deep-Vein Thrombosis

Netherlands, Austria, Italy, South Africa, Israel, United States, France, Australia, Poland, Sweden, Czech Republic
Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Venous Thromboembolism

France, Italy, Czech Republic, Canada, Netherlands, Australia, United States, Poland, South Africa, Sweden, Israel, Denmark, Brazil
Hamilton Health Sciences Corporation
Canadian Institutes of Health Research (CIHR); Canadian Critical Care Trials...

Completed

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)

Critically Ill | Deep Venous Thrombosis

Canada, Australia
McMaster University
Canadian Institutes of Health Research (CIHR); Australian and New Zealand Intensive... and other collaborators

Completed

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

Critical Illness | Deep Venous Thrombosis

United States, Australia, Canada, Saudi Arabia, Brazil, United Kingdom
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Venous Thrombosis | Deep Vein Thrombosis

Italy, Austria, Brazil, Hungary, Netherlands, South Africa, Israel, Australia, Germany
Veniti

Withdrawn

VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism (VERITAS)

Deep Vein Thrombosis | Pulmonary Embolus

New Zealand, Australia
Straub Medical AG

Active, not recruiting

Post-Market Clinical Follow-up Study With ASPIREX®S to Assess the Safety and Effectiveness in the Treatment of DVT (P-MAX)

Deep Vein Thrombosis | Bypass Complication | Dialysis Shunt | Stent Occlusion

Austria, Germany, France, Ireland, Italy
Bayer

Completed

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

Venous Thrombosis | Deep Vein Thrombosis

Belgium, Israel, Italy, Spain, Switzerland, Colombia, New Zealand, Hungary, Canada, Sweden, Austria, Czechia, Germany, Poland, Netherlands, Peru, South Africa, Australia, Brazil
University Of Perugia

Unknown

Aspirin for the Prevention of Recurrent Venous Thromboembolism

Atherosclerosis | Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Italy, Austria
Daiichi Sankyo, Inc.

Completed

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

France, United States, Japan, Denmark, Italy, Russian Federation, Czechia, Germany, India, Israel, Philippines, Taiwan, Ukraine, Australia, Austria, China, Argentina, Belarus, Belgium, Brazil, Canada, Chile, Estonia, Hungary, Korea, Republic... and more
Anthos Therapeutics, Inc.
Itreas

Recruiting

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA)

Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Austria, United States, Taiwan, Australia, Spain, Korea, Republic of, Italy, Hungary, France, Netherlands, Canada, Latvia, Germany, United Kingdom, Norway, Sweden, Ireland, Czechia, Switzerland
Anthos Therapeutics, Inc.
Itreas

Recruiting

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)

Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Austria, United States, Taiwan, Australia, Spain, Japan, Canada, Ireland, Italy, Korea, Republic of, France, Switzerland, Hungary, Netherlands, Latvia, Germany, Norway, Sweden, Czechia, United Kingdom
Bristol-Myers Squibb

Completed

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Deep Vein Thrombosis | Pulmonary Embolism

United States, Argentina, Brazil, Mexico, Russian Federation, Australia, Canada, Hungary, Israel, Turkey, Denmark, Poland, Sweden
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Bristol-Myers Squibb

Completed

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Deep Vein Thrombosis | Pulmonary Embolism

Australia, Mexico, United Kingdom, United States, China, Spain, Denmark, France, Hungary, Israel, Russian Federation, Canada, Belgium, Argentina, Norway, Poland, Ukraine, India, Germany, Romania, Sweden
Sanofi

Completed

SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

Deep Vein Thrombosis | Pulmonary Embolism

United Kingdom, New Zealand, United States, Canada, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, South Africa, Spain, Sweden
Bristol-Myers Squibb

Completed

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (ADVANCE-2)

Deep Vein Thrombosis | Pulmonary Embolism

Italy, Korea, Republic of, China, Spain, South Africa, Colombia, Austria, France, Germany, Israel, Russian Federation, Denmark, Belgium, Singapore, Brazil, Mexico, Norway, Philippines, Poland, Ukraine, India, Malaysia, Hungary, Chile, Czech... and more
GlaxoSmithKline

Completed

Odiparcil For The Prevention Of Venous Thromboembolism

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Fibrillation, Atrial

United States, Israel, Australia, South Africa, Brazil, Canada, Poland, United Kingdom, Ukraine, Lithuania, Russian Federation, India, Latvia
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia

Clinical Trials on Lower Extremity Deep Venous Thrombosis Recurrent in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations